37 results about "Placental cell" patented technology

The present invention provides methods of suppression of tumor cell proliferation and tumor growth using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of tumor suppression, and compositions comprising such cells and cell populations.

Methods, processes and systems for procuring, isolating and cryopreserving fetal placental cells are provided. A population of fetal placental cells is also provided.

The invention discloses a human-derived cell-factor germinal preparation and the preparation method, relating to the technical filed of the healthcare product. The invention contains lecithin which is the lipid membrane-forming material, cholesterin and active component germinal cell factor, with the proportion by weight between them being 2-6:1-4:1-5; the lecithin is selected from egg yolk lecithin or soybean lecithin; the germinal cell factor is selected from the albumen freeze-dry powder of the culture supernatant of human fibroblasts, placental cells, cuticle cells or dermal papilla cells, with abundant cell factors for the hair growth in the culture supernatant; the germinal cell factors are enveloped in the lipid membrane. The rotary evaporating method is adopted in the process to make the product the lipidosome medicament form which can easily permeate the skin barrier. In addition, the product is frozen and dried into the more stable powder, which needs only to be dissolved by the distilled water containing 2% penetrating enhancer azone while in use. The invention is of easy penetration, high skin retention and good curative effect and free of side effect.

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The invention discloses a placenta tissue matrix material. A placenta extracellular matrix is prepared by taking placenta tissue as a raw material through the technologies of tissue preservation, tissue treatment, sterilization, virus inactivation and the like, the placenta extracellular matrix retains a natural matrix structure and basic biological characteristics, and the extracellular matrix particularly retains receptors of various active factors. A preparation method comprises the following steps: tissue pretreatment; sterilization and virus inactivation; tissue DNA removal; decellularization; and preparation of various forms such as gel, sponge or powder from the acellular matrix according to specific clinical requirements. The acellular matrix disclosed by the invention is a specialscaffold material with an active factor receptor, can actively attract active ingredients in a living body into the material, is beneficial to accumulation of cell active ingredients, supports cell migration, adhesion, proliferation and differentiation, and can accelerate damaged tissue repair and local tissue reconstruction.

The invention relates to the technical field of skin care products, in particular to bovine placenta cell exosome freeze-dried powder and a preparation method thereof. An excipient composed of mannitol, trehalose, glycine, glycerin, Tween, albumin and water is combined with the preparation technology, and the prepared bovine placenta cell exosome freeze-dried powder has good stability and biological activity and can be stored for a long time at normal temperature. Experiments show that the bovine placenta cell exosome still keeps good integrity and biological activity after being preserved at the normal temperature of 25 DEG C for 6 months, and is suitable for long-term preservation, transportation and application.

A method for culturing placental potential cell is provided, comprising steps of: (1) obtaining placental cells and / or tissue under aseptic condition; (2) inoculating the placental cells and / or the tissue in a culture medium for culturing, adding cell growth regulators to the culture medium, in such a manner that the placental potential cells grows to make the placental cells and / or the tissue into a proliferative state; (3) culturing the placental potential cells to make the placental potential cells proliferate continuously into cells with characteristics of stem cells. The present invention not only finds the source of human tissues, organs and the continuation of their function, i.e., regenerative potential cells; but also finds a medical and health longevity method, but also finds out the life materials to maintain and support the potential cells, so as to replace drugs with the living material.

The invention discloses a fast separation method for placenta hematopoietic stem cells. The method specifically includes: completely soaking the placenta obtained after normal labor into a buffer solution; cutting the placenta lobule into pieces, and using a buffer solution to sufficiently wash the placenta lobule, and collecting the washing liquid; filtering with a copper screen, and collecting filtrate; using a density gradient centrifugation method to centrifugally separate mononuclear cells, washing with a buffer solution, and using a hematopoietic stem cell culture medium to suspend the acquired cells to obtain the placenta hematopoietic stem cells. The placenta hematopoietic stem cells have the same biological function as umbilical cord blood-source hematopoietic stem cells, and thenumber of the acquired hematopoietic stem cells can satisfy the needs of adult transplant. The separation method has the advantages that the method is simple to operate, convenient and practical; theplacenta hematopoietic stem cells are young in components, wide in source, convenient and easy to obtain and promising in application prospect in stem cell clinical application.

The invention discloses a preparation method of placental cell epimatrix. The method comprises the following steps of (1) unfreezing frozen placenta at the room temperature; (2) separating the placenta tissue; grinding the placenta tissue into tissue fragments on a grinding machine, wherein the size is 0.1mm to 2mm; (3) performing decellularization, virus inactivation and rinsing processing on the tissue fragments; (4) putting the tissue fragments into an environment being -20 DEG C to 80 DEG C over the night; or fast soaking the tissue fragments into dry ice; then, putting the tissue fragments into a freeze drying machine to be subjected to freeze drying for 24h to 48h; obtaining the placental cell epimatrix. The method has the beneficial effects that (1) three kinds of tissue organ decellularization methods are combined; simplicity and easy operation are realized; the decellularization time is greatly shortened; biological ingredients and physical performance cannot be obviously damaged; various cell reaction actors and wound healing factors are maintained to the maximum degree; rich collagen protein, elastic fiber protein and GAGs are contained; the method is beneficial to production enlargement; (2) the decellularization is complete; no allosome tissue antigen is remained.

The invention discloses a placental tissue preservation liquid and a preparation method thereof. The placental tissue preservation liquid includes glucose injection, a serum replacement, gentamicin, amphotericin, trehalose and heparin lithium. The preparation method of the placental tissue preservation liquid includes adding the serum replacement, gentamicin, amphotericin B, magnesium ascorbyl phosphate hydrate, trehalose and heparin lithium into the glucose injection, wherein final concentrations of the ingredients are 0.5-2%, 800 U / mL, 15-30 ug / mL, 0.25-0.5 mg / mL, 0.6-3 mg / mL, and 20-40 U / mL. The placental tissue preservation liquid has clear composition and balanced nutrition, has no evident toxic and side effects on cells, can well maintain activity of in-vitro placental cells, and iseffective in preventing contamination of exogenous microorganisms introduced in the acquisition and transport steps.

A method of comprehensively identifying a specific placental cell lineage of a placental cell sample, applicable to all placental species, is provided. The method employs RT-PCR technology and comprises detecting expression markers unique for each of four trophoblast cell lineages using specifically designed inventive PCR primer pair panels. Diagnostic and prognostic methods, as well as kits and panels related thereto, are also provided.

The invention discloses a sub-totipotent stem cell from cut human umbilical cord or placenta, wherein the cell marker is CD151<+>OCT4<+>CD184<->; the cell grows adhering to the wall in a culture container and can differentiate to the body entoderm, mesoblast and ectoderm tissues. The invention also discloses a preparation method of the sub-totipotent stem cell and an application thereof for preparing drug for treating cell injuries or cell aging diseases, and an application thereof as a carrier cell of a gene treatment drug.

The invention discloses an unfreezing device for placental cells capable of indicating a recovering end point and a recovering method thereof. The device comprises a water bath kettle and a cell-recovering device arranged in the water bath kettle, wherein the cell-recovering device is equipped with a recovering box, a water purifying box and a control panel; the control panel is equipped with a power switch, a filtering control switch, a temperature indicator, a temperature control device and an alarming device; the filtering control switch is used for controlling a water pump to work; a recovering fixed plate is arranged at the top of the recovering box; a fixing hole is formed on the surface of the recovering fixed plate; the hole shape and the hole diameter of the fixing hole are respectively corresponding to the shape and size of a cryopreserving pipe and a cryopreserving bag; and an elastic clamping sheet is arranged on the position, corresponding to the fixing hole, on the lower surface of the recovering fixed plate. According to the device and the method, a user does not need to hold the cryopreserving pipe or the cryopreserving bag in the recovering process and the automation is realized; the defect of manual visual inspection required for checking if completing the recovering is overcome; the pollution problem easily caused by water in water bath can be solved; and the recovering temperature consistency is promoted and the cell activity is promoted.

The invention provides a method for enhancing the differentiation of mesenchymal stem cells into nerve cells. The method comprises the following steps: separating sheep placental cells, then breakingthe cells by using a repeated freeze-thaw process and acquiring sheep placenta extract; adding an appropriate amount of the sheep placenta extract into a stem cell culture solution; and adding a brain-derived neurotrophic factor in the optimal period of stem cell culture so as to obtain differentiated nerve cells. The method of the invention has the advantages that operation process is simple andis easy to learn, and at the same time, the method overcomes problems in proliferation and directed differentiation of bone marrow mesenchymal stem cells into nerve cells.

The present invention relates to isolated nucleic acid molecules conferring on mammalian carcinoma cells an ability to undergo cell migration. Recombinant DNA expression systems and host cells containing the subject nucleic acid molecule, as well as antisense oligonucleotides, are also described. Also disclosed are methods of inhibiting expresssion of the subject nucleic acid molecule, inhibiting production of the encoded protein or polypeptide, inhibiting metastasis of a carcinoma cell in a subject (including in humans), inhibiting migration of carcinoma cell in a subject, detecting the presence of a migrating carcinoma cell in a sample of a subject's tissue or body fluids, and inhibiting the migration of a placental cell into the blood stream of a female mammal.

The invention provides an extraction process of animal embryos or placentas, and relates to the field of bioengineering. The extraction process of the animal embryos or placentas comprises the following steps: S1, separating a placenta from an embryo; S2, breaking a cell structure; S3, performing coarse filtration work; S4, performing centrifugal separation; and S5, performing component extraction(S5.2 embryo component separation and S5.1 placenta component separation). Through the extraction process, laminin, fibronectin and small molecule peptide in animal placenta and embryo separation canbe extracted in a high-purity state, resource waste is reduced, the laminin, the fibronectin and the small molecule peptide can be directly used for research and product preparation due to high purity; and after catalase is used for decomposing hydrogen peroxide, the method can effectively prevent irreversible denaturation of proteins in animal embryos and placental cells due to the action of hydrogen peroxide in the animal embryos and placental cells, and can facilitate protein separation after lipase decomposes fat.

Disclosed is a method of screening a substance for angiotensinogen receptor-modulatory activity. The method includes the steps of contacting placental-derived cells with labeled angiotensinogen and a candidate substance; and then determining whether the candidate substance inhibits the binding of angiotensinogen to the placental-derived cells relative to a control wherein the placental-derived cells are contacted with angiotensinogen in the absence of the candidate substance.

The invention discloses a nano immunoregulation medicine for regulating and controlling the ratio of Treg / Th17 cells in a focus microenvironment and a preparation method and application of the nano immunoregulation medicine. The preparation method comprises the following steps: taking an enzyme substrate polypeptide-PEG modified lipid bimolecular membrane which is subjected to targeted disintegration under the action of an enzyme which is in contact with placenta tissue interstitial fluid and is highly expressed as a shell; a drug carrier modified by surface specific high-expression marker antibodies of important immunomodulatory cells (Treg cells and Th17 cells) of a placenta is used as an inner core, and superparamagnetic ferroferric oxide SPIO nanoparticles, a small molecule drug for regulating functions of the Treg cells and the Th17 cells of the placenta, a therapeutic gene or a combination thereof are loaded in the drug carrier. The nano immunoregulation medicine for regulating and controlling the ratio of the Treg cells to the Th17 cells in the microenvironment of the focus can effectively avoid non-specific medicine absorption of other organs outside the placenta of a maternal body and a fetus, and then delivery and function regulation and control of specific medicines of the Treg cells and the Th17 cells in the placenta are achieved.

The invention relates to a method for separating and purifying hematopoietic stem cells derived from umbilical cord blood and placenta, which relates to a method for separating and purifying stem cells. The invention aims to solve the problem that the conventional hematopoietic stem cell separation and purification method only pays attention to the amount of HES added according to the volume of the blood sample, and does not consider the change of the ratio of red blood cells in different blood samples. The present invention detects the number of red blood cells in the umbilical cord blood and placental cell suspension through a blood analyzer, adds the amount of HES according to a precise ratio, and then realizes the accurate discharge of red blood cells and plasma and the weight of hematopoietic stem cells after purification through formula calculation and blood flow rate controller , realize the precise addition of cryopreservation solution, maximize the yield of hematopoietic stem cells, and follow rules for separation and purification operations, thereby avoiding the addition of HES and cryopreservation solution and the discharge of red blood cell plasma according to personnel experience, ensuring hematopoiesis in the sample The recovery of stem cells and the quality safety after cryopreservation avoid the occurrence of quality deviation caused by personnel operations.

Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and / or compositions comprising placental stem cells. The invention also provides the application of isolated human adherent placental cells in the production for the treatment of an individual having a disruption in the flow of blood in or around the brain.

The invention discloses a method for extracting hematopoietic stem cells in the placenta by using a multifunctional placenta tissue processing device, which relates to the field of biotechnology, and specifically relates to a method for processing placenta tissue. The purpose of the present invention is to solve the problems that placental tissue is easy to be polluted when the placental tissue is opened and treated in the conventional placental cell cleaning and separation process, the process is labor-intensive, the process is incomplete, and the interstitial cells are less obtained. Placental tissue processing and processing methods: 1. Wash the placenta; 2. Break the placenta; 3. Collect placental hematopoietic stem cells, that is, complete the tissue processing of the placenta before separating stem cells. The invention is mainly used for tissue processing of placenta.

Methods and solutions for the preservation and procurement of placental stem cells. A method for collecting stem cells from a placenta includes draining cord blood from the placenta and collecting the drained cord blood in a first collection. The drained placenta is perfused with a first perfusion solution including a placental preservative base solution and a vasodilator. The placenta is perfused with a second perfusion solution including placental preservative base solution, a stem cell releasing agent, an antibiotic, and an anticoagulant, and a predetermined amount of time is allowed to elapse as the first and second perfusion solutions perfuse the placenta. The first and second perfusion solutions, which contain stem cells from the placenta, are then collected in a second collection.

The present invention discloses populations of T cells expressing a chimeric antigen receptor (CAR), wherein said T cells are placental T cells derived from cord blood, placental perfusate, or a mixture thereof. Such populations of cells are shown to be improved in a number of aspects over alternative populations of cells such as those derived from peripheral blood mono-nuclear cell T cells. It also discloses methods of treating cancer, such as a hematologic cancer, e.g., a B cell cancer, or a symptom thereof in a patient in need thereof. These methods comprise administering to the patient an amount of the population of T cells of any one of the invention effective to alleviate the cancer or symptom thereof in the patient.

The invention discloses a method for separating sub-totipotent stem cells from human placenta decidua. The invention particularly relates to the technical field of biomedicine. The method comprises the following steps: tissue extraction, pre-digestion treatment, decidua digestion, centrifugal purification, dilution and filtration, sub-totipotent stem cell separation liquid preparation and sub-totipotent stem cell culture preparation. The method utilizes two enzymolysis processes. Enzymolysis is carried out for the first time to remove miscellaneous cells on the amnion, enzymolysis is carried out on the placenta cells for the second time, a disinfecting and washing procedure is carried out once before each enzymolysis operation so that infectious microbe infections are avoided, human sub-totipotent stem cells with high purity are obtained, when the cell suspension is prepared, one-time centrifugal operation is firstly carried out in the last-time enzymolysis operation, and compared withthe traditional two-step centrifugal operation, the third operation is used, so that the sub-totipotent stem cell separation quality is improved, and the preparation efficiency of the human placentasub-totipotent stem cell is ensured.

Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.

The invention provides a lipid bilayer mimicking the lipid composition of the placenta. The lipid composition provides an in vitro placenta model using the lipid composition of the placental cell membrane.